An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus
Open Access
- 1 January 2018
- journal article
- research article
- Published by Medknow in Perspectives in Clinical Research
- Vol. 9 (1), 15-22
- https://doi.org/10.4103/picr.picr_140_16
Abstract
Aims: This study aims to measure the quality of life (QOL), treatment satisfaction, and tolerability of antidiabetic drugs in patients suffering from type 2 diabetes mellitus (DM). Methods: The prospective, observational study was conducted in consenting patients of type 2 DM attending the outpatient department of a tertiary care hospital in Western India. The QOL instrument for Indian diabetes (QOLID) patients questionnaire and the Diabetes Treatment Satisfaction Questionnaire were administered to all patients at baseline, 3 months, and 6 months of treatment. Tukey–Kramer comparison test was used to analyze the difference in QOLID scores in various domains at baseline, 3 months, and 6 months. WHO-UMC scale, Naranjo's probability scale, Hartwig and Siegel, and Schumock and Thornton modified criteria were used to analyze the adverse drug reactions. Results: A male preponderance was observed in 200 patients enrolled in the study. The mean duration of diabetes was 10.96 ± 5.99 years. The patients received metformin alone (40), metformin and glipizide (47), metformin, glipizide and other oral hypoglycemic agents (OHAs) (78), and OHAs and insulin (35). A significant improvement in fasting and postprandial blood sugar was observed at 6 months as compared to the baseline (P < 0.05). A total of 39 (19.5%) patients suffered from adverse effects to metformin and insulin. Physical health and physical endurance improved in patients receiving metformin alone or in combination with glipizide as compared to patients receiving other OHAs and/or insulin. Treatment satisfaction, highest in patients receiving metformin and least in those receiving insulin, was unaltered during the study period. Conclusions: While polypharmacy is evident, using lesser medicines offers better treatment satisfaction and QOL in DM. Periodic assessment of QOL and treatment satisfaction are recommended in DM.Keywords
This publication has 22 references indexed in Scilit:
- A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathyJournal of Diabetes & Metabolic Disorders, 2014
- Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research–INdia DIABetes (ICMR–INDIAB) studyDiabetologia, 2011
- Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label studyDiabetic Medicine, 2011
- Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 DiabetesDiabetes Care, 2009
- Familial history of diabetes and clinical characteristics in Greek subjects with type 2 diabetesBMC Endocrine Disorders, 2009
- Family History and Prevalence of Diabetes in the U.S. PopulationDiabetes Care, 2007
- Health related quality of life in patients with type I diabetes mellitus: generic & disease-specific measurement.2007
- Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factorsActa Neurologica Scandinavica, 2006
- The Treatment of Hypertension in Adult Patients With DiabetesDiabetes Care, 2002
- Focusing on the preventability of adverse drug reactions.1992